Tony Robbins
Tony Robbins is an entrepreneur, author, philanthropist, and business strategist. He works in business and life coaching, delivering content through audio programs, educational videos, and live seminars. The provided material does not list any academic research publications.
18 claims checked on air: 3 context 2 contradicted 5 overstated 3 supported 5 unverified
What they said on air - supported
The GRAIL Galleri liquid biopsy test can identify circulating cell-free DNA signals for 50 different types of cancer from a routine blood draw.
"Besides the full-body MRI, which is looking for cancers, we do a GRAIL, you know, liquid biopsy, which can find 50 different cancers in your bloodstream. It turns out as cancer cells are growing and dividing very rapidly, some of the cells rupture and you get free-floating DNA in the bloodstream. Well, GRAIL, which is now part of Illumina, started by Jeff Huber—we can we can tell his story—um, they were able to determine and find from a blood draw any number of 50 different cancer DNA sequences and and tell you you've got cancer someplace in your body." (said at 0:22:26)
The GRAIL Galleri multi-cancer early detection (MCED) test analyzes targeted methylation patterns of circulating cell-free DNA (cfDNA) in peripheral blood. In the clinical validation substudy of the Circulating Cell-free Genome Atlas (CCGA) study (NCT02889978; n = 4,077), the test demonstrated high specificity (99.5%) and detected cancer signals across more than 50 different cancer types, while accurately predicting the tissue/organ of origin in 88.7% of true positive cases.
- supports: Clinical validation of a targeted methylation-based multi-cancer early detection test usin… (Annals of oncology : official journal of the European Society for Medical Oncology 2021) · cited 1007x in the literature
"The Circulating Cell-free Genome Atlas study (CCGA; NCT02889978) was a prospective, case-controlled, observational study and demonstrated that a blood-based MCED test utilizing cell-free DNA (cfDNA) sequencing in combination with machine learning could detect cancer signals across multiple cancer types and predict cancer signal origin (CSO) with high accuracy... Cancer signals were detected across >50 cancer types." (abstract, background and results, passage verified)
pubmedfull study (doi) - supports: Real-world data and clinical experience from over 100,000 multi-cancer early detection tes… (Nature communications 2025) · cited 13x in the literature
"To assess real-world performance, we evaluated the Galleri® MCED test (GRAIL, Inc.) across 111,080 individuals (median age 58 years, 55.5% males). This MCED test analyzes methylation patterns of cell-free DNA to detect presence of a cancer signal and predict the anatomical cancer signal origin (CSO) to facilitate diagnostic evaluation." (abstract, results, passage verified)
pubmedfull study (doi)
Cleerly's AI-enabled coronary computed tomography angiography (CCTA) analysis can predict heart attacks up to five years in advance by quantifying soft coronary plaque.
"So he explained to me how it opens up the arteries and how you get this score, and they can predict a heart attack five years in advance and show you what to do." (said at 0:25:46)
AI-guided quantitative coronary computed tomography angiography (AI-QCT, including platforms like Cleerly) quantifies coronary plaque burden and composition, specifically noncalcified (soft) plaque and luminal stenosis. Multicenter prospective observational data, such as the CONFIRM2 registry (median 4.3 years follow-up), demonstrate that AI-derived noncalcified plaque volume and stenosis severity independently predict major adverse cardiovascular events and myocardial infarction over an approximate 5-year horizon, significantly improving risk discrimination over traditional cardiovascular risk scores and guiding targeted medical therapy.
SARS-CoV-2 enters the mitochondria and depletes cellular energy, driving long-term fatigue.
"because I'm sure you know with COVID, it goes into your mitochondria and basically steals some of the energy, that's part of the problem with fatigue" (said at 0:34:48)
Research demonstrates that SARS-CoV-2 viral components (such as the envelope E protein) localize to host cell mitochondria, disrupting mitochondrial membrane potential, electron transport chain activity, and metabolic homeostasis. Clinical studies in patients with post-acute COVID-19 and Long COVID show impaired mitochondrial oxidative phosphorylation, decreased ATP generation, and mitochondrial dysfunction, which are key contributing factors to post-COVID fatigue.
- supports: Platelet mitochondrial function and endogenous coenzyme Q10 levels are reduced in patients… (Bratislavske lekarske listy 2022) · cited 25x in the literature
"Platelet mitochondrial respiratory chain function, oxidative phosphorylation and endogenous CoQ10 level were reduced in the patients after COVID-19." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Mitochondrial metabolic rescue in post-COVID-19 syndrome: MR spectroscopy insights and pre… (Frontiers in immunology 2025) · cited 15x in the literature
"Post-COVID-19 Condition (PCC), impacting 30-90% of survivors, is characterized by persistent fatigue and metabolic dysfunction, often linked to underlying mitochondrial impairment." (abstract, background, passage verified)
pubmedfull study (doi) - supports: SARS-CoV-2 envelope protein mitochondrial localization reveals host metabolic disruption. (The Journal of biological chemistry 2026)
"We demonstrate that severe acute respiratory syndrome coronavirus 2 E localizes to host cell mitochondria and alters mitochondrial structure, metabolism, and redox homeostasis." (abstract, results, passage verified)
pubmedfull study (doi)
Fact-checked episodes
Publications
No PubMed publication profile has been built for this speaker yet.